E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic hepatitis C infection |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008912 |
E.1.2 | Term | Chronic hepatitis C |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of (A) 2 weeks of high dose of ribavirin (“loading”, ≥26 mg/kg/day for 14 days followed by ≥13 mg/kg/day) vs. (B) 4 weeks of ribavirin dosing before initiation of PEG-interferon dosing (“priming”, ≥13 mg/kg/day) followed by concentration targeted (≥ 2.5 mg/L (10.25 μmol/L) 28 days after initiation of ribavirin therapy) dosing of ribavirin in combination with peginterferon alpha-2a in interferon naïve patients with chronic hepatitis C (CHC) virus genotype 1 infection as compared to (C) standard-of-care dosing of ribavirin (≥13 mg/kg/day without monitoring of ribavirin concentrations) in combination with peginterferon alpha-2a as evaluated by the early viral kinetic response and SVR measured by effect on the initial decline of HCV-RNA (during the first days after initiating peginterferon and ribavirin therapy) and second phase decline (day 7 to week 12 of therapy).
|
|
E.2.2 | Secondary objectives of the trial |
To prospectively evaluate: •efficacy of 2 week loading or 4 week priming as evaluated by the proportion of patients achieving VRVR, RVR, cEVR, and pEVR •predictive value of monitoring of viral load at day 0, 3, 7 and 28 •association between the trough concentrations of ribavirin and the therapeutic efficacy •association between plasma IP-10 and the therapeutic efficacy. •effect of IL-28B ploymorfism on the viral kinetic response. •effect of baseline vitamin D concentrations on the viral kinetic response. •effect of baseline IP-10 concentrations on the viral kinetic response. •association between liver histology and the therapeutic efficacy. •association between liver stiffness as evaluated by the FibroScan and the therapeutic efficacy. •association between liver fibrosis as evaluated by the GUCI and APRI indexes as well as hyaluronic acid, and the therapeutic efficacy. •association between BMI and age and the therapeutic efficacy. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Written informed consent • Male and female patients >/=18 years of age • Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test • Serum HCV-RNA >/=15 IU/mL. • HCV genotype 1 infection confirmed within the past 2 years preceding the initiation of test drug dosing. • Compensated liver disease (Child-Pugh Grade A clinical classification) • Patients with cirrhosis or transition to cirrhosis must have an abdominal ultrasound, CT scan, or MRI scan without evidence of hepatocellular carcinoma and a serum AFP ≤100 ng/mL within 2 months of randomization • Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug • All fertile males and females receiving ribavirin must be using effective contraception during treatment and during 4 months for female patients / 7 months for male patients after end of treatment • Subject must weigh between 45 and 105 kg at screening
|
|
E.4 | Principal exclusion criteria |
• Women with ongoing pregnancy or breast feeding • IFN/ peg-interferon with or without ribavirin therapy at any previous time • Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) *6 months prior to the first dose of study drug • Any investigational drug </=6 weeks prior to the first dose of study drug. • HCV genotype 2, 3, 4, 5, 6, or 7 infection. • Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, anti-HIV Ab • Evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures) • History or other evidence of decompensated liver disease • Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening • Serum creatinine level >2 mg/dl (>124 µmol/L) or creatinine clearance ≤50 ml/minute at screening • Severe psychiatric disease, especially depression, as judged by the treating physician. • History of a severe seizure disorder or current anticonvulsant use • History of immunologically mediated disease, severe chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study • Thyroid dysfunction not adequately controlled (TSH and T4 levels out of normal range) • Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration) or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension • Evidence of drug abuse (including excessive alcohol consumption) in accordance with local therapeutic traditions. • Inability or unwillingness to provide informed consent or abide by the requirements of the study • Male partners of women who are pregnant • Hemoglobin <12 g/dL in women or <13 g/dL in men at screening. • Any patient with an increased baseline risk for anemia (e.g. thalassemia major, spherocytosis, history of GI bleeding, etc) or for whom anemia would be medically problematic coagulopathy. • Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would not be well-tolerated
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The early virological response as measures by the decline in HCV-RNA during the first 12 weeks (in particular the first and second phase decline) of peginterferon alpha-2a and ribavirin therapy in the three study arms. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |